Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Medical Equipment

FluoroPharma Medical Inc

+ Add to Watchlist


0.3550 USD 0.0300 9.23%

As of 20:10:04 ET on 05/29/2015.

Snapshot for FluoroPharma Medical Inc (FPMI)

Open: 0.3250 Day's Range: 0.3150 - 0.3600 Volume: 51,500
Previous Close: 0.3250 52wk Range: 0.2809 - 0.7900 1-Yr Rtn: -50.76%

Stock Chart for FPMI

No chart data available.
  • FPMI:US 0.3550
  • 1D
  • 1M
  • 1Y
Interactive FPMI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for FPMI

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 10.45
Shares Outstanding (M) 29.43
30 Day Average Volume 21,236
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for FPMI

No data available

Company Profile & Key Executives for FPMI

FluoroPharma Medical Inc. is a molecular imaging company. The Company engages in the discovery, development and commercialization of proprietary diagnostic imaging products. FlouroPharma's initial focus is the development of positron emission tomography (PET) imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease.

Johan M Spoor "Thijs"Chairman/President/CEOBoyan GoumnerovVP:Clinical Trials/COO
Edward L Lyons Jr "Ed"VP:Marketing
More Company Profile & Key Executives for FPMI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil